跳至主要内容
临床试验/NCT04326946
NCT04326946进行中(未招募)不适用

International Alfapump Cohort Study: in Patients With Refractory Ascites Due to Liver Cirrhosis or Malignant Ascites With a Life Expectancy of 6 Months or Less

Sequana Medical N.V.2 个研究点 分布在 2 个国家目标入组 400 人开始时间: 2018年8月14日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
400
试验地点
2
主要终点
Patient survival at 6 months post implant

研究概览

简要总结

This Registry is designed to follow patients who have been implanted with an alfapump system, which is a newly marketed product from Sequana Medical AG, a Swiss Medical Device company.

详细描述

In a real-world setting, all patients implanted with an alfapump system according to it's intended use, not participating in another clinical study in which the alfapump is studied.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • All patients implanted with an alfapump are eligible for this registry

排除标准

  • Patients younger than 18 years
  • Pregnancy
  • Inability to operate the Smart Charger to recharge the alfapump
  • Participating in another study in which the alfapump is studied

结局指标

主要结局

Patient survival at 6 months post implant

时间窗: 6 months post-implant

The primary outcome will be patient survival with a functional alfapump system at 6 months.

次要结局

  • Clinical impact on liver and renal function in liver & renal blood lab panel(2 years)
  • Impact of the alfapump on ascites symptoms related quality of life on patient activity(1 week pre-implant, Day 0 Implant, 4 weeks-, 8 weeks-, 16 weeks-, 24 weeks- and 48 weeks post implant)
  • To assess safety at 1-month post implant for procedure related incidents.(1 month post implant)
  • Clinical impact on ECOG(2 years)
  • To assess occurrence of (major) reportable events.(2 years)
  • Impact of the alfapump on ascites symptoms related quality of life(2 years)

研究者

发起方
Sequana Medical N.V.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验